RESUMO
The pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide, a cyclooxygenase-2 inhibitor, were investigated in rats. Celecoxib was metabolized extensively after i.v. administration of [(14)C]celecoxib, and elimination of unchanged compound was minor (less than 2%) in male and female rats. The only metabolism of celecoxib observed in rats was via a single oxidative pathway. The methyl group of celecoxib is first oxidized to a hydroxymethyl metabolite, followed by additional oxidation of the hydroxymethyl group to a carboxylic acid metabolite. Glucuronide conjugates of both the hydroxymethyl and carboxylic acid metabolites are formed. Total mean percent recovery of the radioactive dose was about 100% for both the male rat (9.6% in urine; 91.7% in feces) and the female rat (10.6% in urine; 91.3% in feces). After oral administration of [(14)C]celecoxib at doses of 20, 80, and 400 mg/kg, the majority of the radioactivity was excreted in the feces (88-94%) with the remainder of the dose excreted in the urine (7-10%). Both unchanged drug and the carboxylic acid metabolite of celecoxib were the major radioactive components excreted with the amount of celecoxib excreted in the feces increasing with dose. When administered orally, celecoxib was well distributed to the tissues examined with the highest concentrations of radioactivity found in the gastrointestinal tract. Maximal concentration of radioactivity was reached in most all tissues between 1 and 3 h postdose with the half-life paralleling that of plasma, with the exception of the gastrointestinal tract tissues.
Assuntos
Anti-Inflamatórios não Esteroides/farmacocinética , Sulfonamidas/farmacocinética , Animais , Área Sob a Curva , Bile/metabolismo , Ductos Biliares/fisiologia , Biotransformação , Celecoxib , Cromatografia Líquida de Alta Pressão , Fezes/química , Feminino , Meia-Vida , Injeções Intravenosas , Masculino , Pirazóis , Ratos , Ratos Sprague-Dawley , Sulfonamidas/administração & dosagem , Distribuição TecidualRESUMO
A flow injection/tandem mass spectrometric assay was developed to quantitate SC-68328 in dog plasma using its stable isotopic analog [13C4]SC-68328 as an internal standard (IS). Since SC-68328, a manganese-based superoxide dismutase mimetic, is very unstable, very polar and adheres to silica-based high-performance liquid chromatographic columns, the analyte and IS were derivatized to their bis-isothiocyanate forms followed by a liquid-liquid extraction with methylene chloride and analyzed using positive ion electrospray mass spectrometric detection. SC-68328 was quantitated using the peak-height ratio of SC-68328 to its IS using MS/MS in the multiple reaction monitoring mode. The lower limit of quantitation of the assay was 0.25 microg ml(-1) SC-68328 in dog plasma with an inter-day precision of 11.8% and an accuracy of 113% (n = 12). Acceptable precision and accuracy were also obtained for concentrations in the calibration curve range (0.25-10 microg ml(-1) SC-68328 in dog plasma).
Assuntos
Análise Química do Sangue/métodos , Espectrometria de Massas/métodos , Compostos Organometálicos/sangue , Animais , Análise Química do Sangue/normas , Análise Química do Sangue/estatística & dados numéricos , Cães , Espectrometria de Massas/normas , Espectrometria de Massas/estatística & dados numéricos , Compostos Organometálicos/química , Compostos Organometálicos/farmacologia , Controle de Qualidade , Superóxido Dismutase/farmacologiaRESUMO
The pharmacokinetics of celecoxib, a cyclooxygenase-2 inhibitor, was characterized in beagle dogs. Celecoxib is extensively metabolized by dogs to a hydroxymethyl metabolite with subsequent oxidization to the carboxylic acid analog. There are at least two populations of dogs, distinguished by their capacity to eliminate celecoxib from plasma at either a fast or a slow rate after i.v. administration. Within a population of 242 animals, 45.0% were of the EM phenotype, 53.5% were of the PM phenotype, and 1.65% could not be adequately characterized. The mean (+/-S.D.) plasma elimination half-life and clearance of celecoxib were 1.72 +/- 0.79 h and 18.2 +/- 6.4 ml/min/kg for EM dogs and 5.18 +/- 1.29 h and 7.15 +/- 1.41 ml/min/kg for PM dogs. Hepatic microsomes from EM dogs metabolized celecoxib at a higher rate than microsomes from PM dogs. The cDNA for canine cytochrome P-450 (CYP) enzymes, CYP2B11, CYP2C21, CYP2D15, and CYP3A12 were cloned and expressed in sf 9 insect cells. Three new variants of CYP2D15 as well as a novel variant of CYP3A12 were identified. Canine rCYP2D15 and its variants, but not CYP2B11, CYP2C21, and CYP3A12, readily metabolized celecoxib. Quinidine (a specific CYP2D inhibitor) prevented celecoxib metabolism in dog hepatic microsomes, providing evidence of a predominant role for the CYP2D subfamily in canine celecoxib metabolism. However, the lack of a correlation between celecoxib and bufuralol metabolism in hepatic EM or PM microsomes indicates that other CYP subfamilies besides CYP2D may contribute to the polymorphism in canine celecoxib metabolism.
Assuntos
Inibidores de Ciclo-Oxigenase/metabolismo , Sistema Enzimático do Citocromo P-450/genética , Isoenzimas/efeitos dos fármacos , Polimorfismo Genético , Prostaglandina-Endoperóxido Sintases/efeitos dos fármacos , Sulfonamidas/metabolismo , Animais , Celecoxib , Clonagem Molecular , Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2 , Cães , Etanolaminas/metabolismo , Feminino , Humanos , Masculino , Proteínas de Membrana , Microssomos Hepáticos/metabolismo , Pirazóis , Quinidina/farmacologiaRESUMO
PURPOSE: To determine mechanism of food effects observed with bidisomide but not with the structurally similar drug, disopyramide. METHODS: Food effect studies of bidisomide and disopyramide were conducted with and without a standardized high fat meal in healthy subjects and in the dog. Intestinal metabolism of disopyramide and absorption of the metabolites were examined after oral administration of the drug to the dogs with portal vein canula implanted. Effects of food or a mixture of amino acids on metabolism of [14C]disopyramide were examined after intraportal infusion of the drug with and without high fat meal and after drug infusion into portal vein with the amino acid mixture, respectively. RESULTS: The systemic availability of bidisomide was markedly reduced with food in humans, whereas the systemic availability of disopyramide did not change notably. In the dog, the systemic availability of bidisomide was also reduced with food. The systemic availability of disopyramide did not change with food. This was due to the fact that reduction in absorption was compensated by reduction of metabolism. There was no evidence for reduction in hepatic and intestinal metabolism with food. CONCLUSIONS: The apparent reduction in disopyramide metabolism with food may be due to an increase in colonal and/or lymphatic absorption. Food effects on the apparent systemic availability of bidisomide and disopyramide in the dog were similar to those in the rat. However, there was substantial species difference in the mechanism of food effects.
Assuntos
Antiarrítmicos/farmacocinética , Gorduras na Dieta/administração & dosagem , Disopiramida/farmacocinética , Interações Alimento-Droga , Piperidinas/farmacocinética , Adulto , Animais , Antiarrítmicos/sangue , Área Sob a Curva , Disponibilidade Biológica , Estudos Cross-Over , Gorduras na Dieta/sangue , Disopiramida/sangue , Cães , Feminino , Humanos , Absorção Intestinal , Fígado/metabolismo , Masculino , Piperidinas/sangue , Especificidade da Espécie , Relação Estrutura-AtividadeRESUMO
PURPOSE: To determine whether the rat is a good animal model for the food effects observed with bidisomide but not with the structurally similar antiarrhythmic drug, disopyramide in man and to explore a reason for the differences in the food effects of these compounds. METHODS: The following effects on the absorption of bidisomide and/or disopyramide were examined in the rat: Food effects, gastrointestinal transit time under fasting and nonfasting conditions, pH effects, hypertonic solution effect of NaCl and glucose, bile effects, permeability, inhibitory effects by Gly, Gly-Gly, Gly-Pro, glucose and mannitol and drug binding to food. RESULTS: Remarkable food effects were observed with bidisomide but not with disopyramide. There was no difference in the GI transit time with and without food. The pH effect with and without food was similar. Effect of salt concentrations on bidisomide and disopyramide was similar. There was no bile effect on absorption of both compounds. Binding of bidisomide and disopyramide to food was similarly low. The apparent permeability of bidisomide was much lower than disopyramide especially in the ileum and its absorption was more inhibited by Gly, Gly-Gly and Gly-Pro. CONCLUSIONS: In the rat, as previously seen in humans, the food effect was observed with bidisomide but not with disopyramide. This difference was in part due to both lower intestinal permeability of bidisomide compared to disopyramide and greater inhibition of absorption by the amino acid, Gly and the dipeptides, Gly-Gly and Gly-Pro.
Assuntos
Antiarrítmicos/farmacocinética , Disopiramida/farmacocinética , Interações Alimento-Droga , Piperidinas/farmacocinética , Animais , Bile/metabolismo , Colo/metabolismo , Jejum , Trânsito Gastrointestinal/efeitos dos fármacos , Concentração de Íons de Hidrogênio , Íleo/metabolismo , Absorção Intestinal/efeitos dos fármacos , Jejuno/metabolismo , Masculino , Permeabilidade , Ratos , Cloreto de Sódio/farmacologiaRESUMO
1. SC-52151, an HIV protease inhibitor, is mainly metabolized by CYP3A4 and is poorly bioavailable after oral administration. After i.v. administration of SC-52151 to the female beagle dog (2.5 mg/kg), SC-52151 was rapidly eliminated in plasma with an elimination half-life of about 1 h, a plasma clearance of 44 ml/min/kg and an apparent steady-state volume distribution of 2.2 litre/kg. The high value of plasma clearance of SC-52151 suggests an extensive hepatic first-pass metabolism since SC-52151 is highly protein bound and does not partition itself into red blood cells. 2. The extensive hepatic first-pass metabolism was reduced by coadministration of a CYP3A4 inhibitor, ketoconazole. 3. Dogs were dosed daily with ketoconazole at dose of 100 mg ketoconazole per dog (approximately 10 mg/kg) for 5 days prior to the initiation of coadministration of SC-52151 for 15 days. The doses used for SC-52151 was 0, 60 and 120 mg SC-52151/kg/day (divided t.i.d., 8-h dosing interval). Coadministration of ketoconazole improved the bioavailability of SC-52151 from 4.1 to 9.6% and also improved the Cmax of SC-52151 from 0.41 to 0.83 microgram/ml. 4. Although the absolute bioavailability of SC-52151 was still low (approximately 10%), the Cmax and AUC achieved in this study were satisfactory for conducting chronic toxicology studies. No toxicity associated with the coadministration of ketoconazole was evident. Results from this study suggest that coadministration of ketoconazole might be a practical approach to increase the exposure of SC-52151 in both preclinical and clinical studies.
Assuntos
Antifúngicos/farmacocinética , Inibidores Enzimáticos/farmacocinética , Inibidores da Protease de HIV/farmacocinética , Isoenzimas/antagonistas & inibidores , Cetoconazol/farmacocinética , Ureia/análogos & derivados , Administração Oral , Animais , Antifúngicos/toxicidade , Disponibilidade Biológica , Inibidores das Enzimas do Citocromo P-450 , Cães , Sinergismo Farmacológico , Inibidores Enzimáticos/toxicidade , Feminino , Inibidores da Protease de HIV/toxicidade , Meia-Vida , Injeções Intravenosas , Cetoconazol/toxicidade , Taxa de Depuração Metabólica , Ureia/farmacocinética , Ureia/toxicidadeRESUMO
The metabolic fate of SC-57461, N-methyl-N-[3-[4-(phenylmethyl)-phenoxy]propyl]-beta-alanine, a potent and specific inhibitor of the leukotriene A4 hydrolase, was determined by LC/MS/MS, NMR and GC/MS in male Sprague-Dawley rats. The major metabolites of SC-57461 in rats were the desmethyl metabolite, the hydroxylated metabolite, the N-oxide metabolite, the hydroxylamine metabolite, and the propionic acid metabolite. The N-oxide metabolite was found to be stable in the rat plasma and urine, but was unstable in most organic solvents (methanol, acetonitrile, and methylene chloride, etc.) because of the classic Cope reaction of the N-oxide, which led to the formation of the corresponding hydroxylamine product and acrylic acid. The hydroxylamine metabolite and acrylic acid were reactive in the biomatrix and could not be isolated in the in vivo samples. However, formation of the hydroxylamine metabolite and acrylic acid from the N-oxide metabolite in methylene chloride was verified by NMR. The propionic acid metabolite was found to be the common metabolite shared by SC-57461, N-oxide metabolite, as well as the hydroxylamine metabolite, which suggested a sequential metabolism of SC-57461 in rats. The ultimate fate of the propionic acid metabolite was incorporation into rat glycerolipid metabolism as a result of its structural similarity to aryl-substituted propionic acid, a known class of compounds that can be incorporated into rat glycerolipid metabolism. Finally, the isolated hydroxylated metabolite and the N-desmethyl metabolite were found to have excellent inhibitory effects toward leukotriene A4 hydrolase and therefore were the major active metabolites of SC-57461 in rats.
Assuntos
Inibidores Enzimáticos/metabolismo , Epóxido Hidrolases/antagonistas & inibidores , beta-Alanina/análogos & derivados , Administração Oral , Animais , Radioisótopos de Carbono , Cromatografia Líquida de Alta Pressão , Inibidores Enzimáticos/administração & dosagem , Infusões Intravenosas , Espectroscopia de Ressonância Magnética , Masculino , Espectrometria de Massas/métodos , Ratos , Ratos Sprague-Dawley , beta-Alanina/administração & dosagem , beta-Alanina/metabolismoRESUMO
1. Metabolism of bidisomide, a novel antiarrhythmic agent, was studied in man, and was not extensive as evidenced by the fact that approximately 60 and 70% of the radioactive doses were recovered as the parent drug after i.v. and oral administration respectively. 2. The mass spectra of bidisomide metabolites indicate that the two major metabolic pathways of bidisomide were hydroxylation of the piperidine ring and N-dealkylation. The latter occurred on the side chain containing the piperidine ring or the isopropyl group. The N-dealkylated metabolite on the side chain containing the piperidine ring was cyclized to result in a pyrrolidone metabolite. 3. The N-dealkylated metabolite, desisopropyl bidisomide, was identified by comparing its high resolution mass spectrum to that of authentic desacetyl bidisomide. 4. In the hydroxylation pathway, both mono- and dihydroxylated metabolites of the piperidine ring were observed. The exact location of the hydroxyl groups on the piperidine ring was not determined.
Assuntos
Antiarrítmicos/metabolismo , Piperidinas/metabolismo , Administração Oral , Antiarrítmicos/administração & dosagem , Humanos , Injeções Intravenosas , Espectrometria de Massas , Piperidinas/administração & dosagemRESUMO
PURPOSE: The in vitro fate of an ester prodrug, glycovir, was studied to determine if the species differences in the bioavailability of pharmacologically active SC-48334 observed after glycovir administration and not observed after SC-48334 administration is due to species differences in ester hydrolysis rate or species differences in absorption of the prodrug itself, and to determine the site(s) of ester hydrolysis which contributes most to species differences in the bioavailability of SC-48334 if any. METHODS: Glycovir was incubated with small intestinal mucosa, liver S9 fractions, whole blood, red blood cells (RBC) and plasma of the rat, dog, monkey (cynomolgus and rhesus) and man, and glycovir concentrations were determined by HPLC. RESULTS: The relative bioavailabilities of SC-48334 after prodrug administration to the rat, dog, monkey and man were 99, 15, 42 and 37%, respectively. After SC-48334 administration, SC-48334 was rapidly and similarly well absorbed in all species. The hydrolysis rate in the small intestinal mucosa was well correlated with the relative bioavailability of SC-48334 after prodrug administration. Among different species the hydrolysis rate of glycovir in liver S9 fractions, blood, RBC and plasma did not parallel those in the mucosa of the small intestine. CONCLUSIONS: The species differences in bioavailability of SC-48334 with the prodrug were due to species differences in hydrolysis rates of the prodrug in small intestinal mucosa. The monkey was a good animal model for prediction of esterase activity in human small intestine and relative bioavailability in man.
Assuntos
1-Desoxinojirimicina/análogos & derivados , Antivirais/farmacocinética , Butiratos/farmacocinética , Esterases/metabolismo , HIV/efeitos dos fármacos , Piperidinas/farmacocinética , Pró-Fármacos/farmacocinética , 1-Desoxinojirimicina/sangue , 1-Desoxinojirimicina/farmacocinética , Adolescente , Adulto , Animais , Antivirais/sangue , Disponibilidade Biológica , Butiratos/sangue , Cães , Feminino , Soropositividade para HIV/metabolismo , Humanos , Hidrólise , Técnicas In Vitro , Absorção Intestinal , Mucosa Intestinal/metabolismo , Fígado/metabolismo , Macaca fascicularis , Masculino , Piperidinas/sangue , Ratos , Especificidade da Espécie , Frações Subcelulares/metabolismoAssuntos
Anti-Inflamatórios não Esteroides/metabolismo , Anti-Inflamatórios não Esteroides/farmacocinética , Benzamidas/metabolismo , Benzamidas/farmacocinética , Benzopiranos/metabolismo , Benzopiranos/farmacocinética , Receptores do Leucotrieno B4/antagonistas & inibidores , Administração Oral , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Benzamidas/administração & dosagem , Benzopiranos/administração & dosagem , Disponibilidade Biológica , Cães , Cobaias , Injeções Intravenosas , Macaca fascicularis , Macaca mulatta , Masculino , Ratos , Especificidade da EspécieRESUMO
A method for the measurement of angiotensin II levels in dog plasma is described. The method is similar to previously published assays in that in couples gradient high-performance liquid chromatography (HPLC) with radioimmunoassay (RIA) and requires blood sample collection and processing to plasma in the presence of protease inhibitors. The unique feature of the present method is that it utilized a commercially available angiotensin II RIA run under nonequilibrium conditions. Performing the angiotensin II RIA under nonequilibrium conditions increased RIA sensitivity to allow for a minimal detectable limit of 0.75 pg/mL, a limit of detection not achievable with current commercially available RIAs. This lower limit of detection will now allow for the measurement of circulating levels of angiotensin II. Quality control pools of dog plasma fortified with 4.59-50 pg/mL angiotensin II were assayed and analytical recoveries (ARs) and coefficients of variation (CV) of 72.2%-111% and 3.67%-19.0% were observed for the respective pools.
Assuntos
Angiotensina II/sangue , Radioimunoensaio/métodos , Angiotensina II/efeitos dos fármacos , Animais , Coleta de Amostras Sanguíneas , Cromatografia Líquida de Alta Pressão , Cães , Masculino , Inibidores de Proteases/farmacologia , Controle de Qualidade , Radioimunoensaio/normas , Kit de Reagentes para Diagnóstico , Reprodutibilidade dos TestesRESUMO
The in vitro serum protein binding and erythrocyte uptake of [3H]misoprostol acid ([3H]MPA; SC-30695), an active metabolite of the prostaglandin E1 (PGE1) analogue misoprostol, was determined in the blood of young (20-40 years) and elderly subjects (64 years or older) at concentrations ranging between 20 and 5000 pg/mL. The effect of selected other drugs on the displacement of [3H] MPA from the binding sites was also investigated. [3H]MPA serum binding (between 81 and 89 %) was similar and concentration independent in the young and elderly subjects and the erythrocyte partitioning coefficient was about 1, indicating the absence of a significant accumulation of MPA in red blood cells. Both the plasma and serum protein binding of [3H] MPA were substantially reduced in the presence of high (> 100 microg/mL) concentrations of salicylic acid. In an in vivo study, the single-dose pharmacokinetics of MPA did not change significantly when misoprostol (200 microg) was given alone or concomitantly with 975 mg of aspirin. These findings indicate that MPA is displaced from its protein binding sites only by high concentrations of salicylic acid and that this displacement is unlikely to be of clinical significance with the usual therapeutic doses of aspirin.
Assuntos
Antiulcerosos/farmacocinética , Proteínas Sanguíneas/metabolismo , Misoprostol/análogos & derivados , Salicilatos/farmacologia , Adulto , Estabilidade de Medicamentos , Eritrócitos/metabolismo , Humanos , Misoprostol/química , Misoprostol/farmacocinética , Ligação Proteica , Ácido SalicílicoRESUMO
In vitro metabolism studies of potassium canrenoate (PC) were conducted to examine whether spironolactone (SP) and/or its sulfur-containing metabolites inhibit the PC metabolic pathways to mutagenic metabolites and to elucidate the mechanism for any observed inhibitory effect. The mechanistic study was conducted using liver microsomes prepared from male and female rats with and without pretreatment of a cytochrome (Cyt) P-450IIIA inducer [pregnenolone-16 alpha-carbonitrile (PCN) or dexamethasone (DEX)] and with and without a Cyt P-450IIIA inhibitor, triacetyloleandomycin (TAO). The present study demonstrates that SP and its sulfur-containing metabolite 7 alpha-thio-spirolactone substantially inhibited the formation of promutagen 6 beta, 7 beta-epoxycanrenone (6 beta, 7 beta-epoxy-CAN) from PC. The sulfur-containing metabolite of SP that inhibit promutagen formation were not formed from PC, although a glutathione conjugate of PC was formed. The formation rate of 6 beta, 7 beta-epoxy-CAN was greater in liver microsomes prepared from rats pretreated with a Cyt P-450IIIA inducer (PCN or DEX) than in liver microsomes prepared from the untreated rats. The formation rate of the epoxide metabolite was lower after in vitro addition of TAO. Pretreatment of animals with TAO 4 hr before sacrifice produced similar results. Erythromycin, which is N-demethylated by Cyt P-450IIIA, also reduced the formation rate of 6 beta, 7 beta-epoxy-CAN. Inhibition of PC metabolism to 6 beta, 7 beta-epoxy-CAN by TAO and erythromycin, and its induction by DEX and PCN, suggest involvement of Cyt P-450IIIA, which is in turn inhibited by SP and 7 alpha-thio-spirolactone.
Assuntos
Hidrocarboneto de Aril Hidroxilases , Ácido Canrenoico/metabolismo , Sistema Enzimático do Citocromo P-450/metabolismo , Compostos de Epóxi/metabolismo , Oxirredutases N-Desmetilantes/metabolismo , Espironolactona/farmacologia , Enxofre/metabolismo , Animais , Radioisótopos de Carbono , Citocromo P-450 CYP3A , Eritromicina/farmacologia , Feminino , Glutationa/metabolismo , Cinética , Masculino , Microssomos Hepáticos/enzimologia , Microssomos Hepáticos/metabolismo , Ratos , Ratos Endogâmicos , Espironolactona/análogos & derivados , Espironolactona/metabolismo , Compostos de SulfidrilaRESUMO
The pharmacokinetics of a novel antiarrhythmic drug, actisomide, were examined in the rat, dog, monkey, and human. The terminal half-life of actisomide was similar (1.15-1.89 hr) across species, regardless of dose. The total plasma clearance was higher in the monkey (13.5-16.4 mL/min/kg) than in the dog (9.01-9.32 mL/min/kg), rat (8.6-9.8 mL/min/kg), or human (6.79 +/- 1.07 mL/min/kg). Excretion of the parent drug was higher in urine than in feces in the dog and rat, whereas in the monkey and human, urinary and fecal excretions of actisomide were similar. In humans, atypical plasma concentration-time curves with double peak concentrations were observed following oral doses. Systemic availability of actisomide was higher in the dog than in the rat, monkey, and human. Further, the systemic availability appeared to increase with dose in the rat and monkey. The species-dependent systemic availability appeared to be due primarily to species-dependent absorption of actisomide, and not to species-dependent first-pass metabolism, biliary excretion, and/or renal elimination. The absorption of actisomide in the rat and its in vitro uptake in CaCo-2 cells were pH dependent. The higher systemic availability of actisomide observed in the dog may be due partly to the higher pH in the gastrointestinal (GI) tract of the dog. However, the pH differences in the GI tract of the different species alone did not appear to be enough to explain the difference in systemic availability of actisomide.
Assuntos
Antiarrítmicos/farmacocinética , Pirimidinonas/farmacocinética , Administração Oral , Adulto , Animais , Antiarrítmicos/sangue , Antiarrítmicos/urina , Bile/metabolismo , Linhagem Celular , Cromatografia Líquida de Alta Pressão , Cães , Fezes/química , Feminino , Humanos , Injeções Intravenosas , Absorção Intestinal , Macaca mulatta , Masculino , Pirimidinonas/sangue , Pirimidinonas/urina , Ratos , Especificidade da EspécieRESUMO
In vitro and in vivo experiments were conducted with double- and single-layer albuterol transdermal pads designed for once-a-day application. In the in vitro experiments, dissolution of albuterol from pads and permeation of albuterol through hairless mouse skin were monitored. In the in vivo experiments, pads were applied to the chest area of four female rhesus monkeys (Macaca mulata), and an albuterol aqueous solution was injected into the saphenous vein of the same animals in a crossover design. The amount lost from pads applied to monkeys was monitored by analysis of pad residue. Blood samples were withdrawn at regular intervals and analyzed by a high-performance liquid chromatography-fluorescence method. Skin irritation due to the pad was measured by a modified Draize score test. The amounts released from the two formulations were similar. The amount released was, however, dependent on the technique used and decreased in the following manner: pad dissolution greater than in vivo amount lost from pads applied to monkeys greater than in vitro permeation through hairless mouse skin. The pharmacokinetic parameters determined after intravenous and transdermal administration were as follows: terminal half-life, 2.26 +/- 0.45 h; apparent volume of distribution, 1935 +/- 37.2 mL.kg-1; and total body clearance, 612.0 +/- 118 mL.h-1.kg-1. The average concentrations in serum after application of single- and double-layer pads were 44.60 +/- 16.40 and 62.50 +/- 8.00 ng/mL, respectively. Further, the amount lost from pads applied to monkeys correlated with the respective amount absorbed in monkeys, as calculated from the average concentration in serum and clearance.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Albuterol/administração & dosagem , Sistemas de Liberação de Medicamentos , Administração Cutânea , Albuterol/efeitos adversos , Albuterol/farmacocinética , Animais , Disponibilidade Biológica , Preparações de Ação Retardada , Técnicas In Vitro , Injeções Intravenosas , Macaca mulatta , Masculino , Camundongos , Camundongos Pelados , Pele/efeitos dos fármacos , Absorção CutâneaRESUMO
Nasal absorption of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L-leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (I), a renin inhibitor, was evaluated in two rat nasal models, one involving surgery and the other requiring no surgical intervention. Oleic acid/monoolein emulsion formulations were tested along with a control PEG 400 solution. The percent absolute bioavailability of the compound was enhanced from 3-6% (PEG 400 solution) to 15-27% when the emulsion formulations were used. The different nasal model techniques (with and without surgery) did not produce any statistical difference in the absolute bioavailability values for I. Emulsion formulations did not produce appreciable damage as assessed morphologically. It is suggested that emulsion formulations containing membrane adjuvants such as oleic acid and monoolein can be used to enhanced the nasal delivery of low-bioavailable, lipid-soluble drugs.
Assuntos
Dipeptídeos/administração & dosagem , Morfolinas/administração & dosagem , Mucosa Nasal/efeitos dos fármacos , Renina/antagonistas & inibidores , Administração Intranasal , Animais , Disponibilidade Biológica , Cromatografia Líquida de Alta Pressão , Dipeptídeos/farmacocinética , Emulsões , Glicerídeos/química , Masculino , Morfolinas/farmacocinética , Ácido Oleico , Ácidos Oleicos/química , Ratos , Ratos Sprague-Dawley , Solubilidade , Ácido Taurocólico/químicaRESUMO
The oral delivery of O-(N-morpholino-carbonyl-3-L-phenylaspartyl-L- leucinamide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylhetane (I), a new renin inhibitor, was studied in the in vivo rat model using emulsion formulations. The components of the emulsion formulations were chosen based on their proposed effects on membrane structure, membrane fluidity, and solute transport. The percent absolute bioavailability (%AB) of I was increased from 0.3% (water suspension) to 5.1% when long-chain unsaturated fatty acid (oleic acid, linoleic acid, etc.)- and mono- and diglyceride (monolein, dilaurin, etc.)-containing emulsion formulations were used. Considering very high first-pass liver extraction of the compound (80%), it is suggested that emulsion formulations increased the intestinal transport of the compound significantly. The solubility of I in aqueous media with and without bile salt (20 mM) was found to be low (approximately 1 micrograms/ml). Incubation in 0.01 N HCl did not affect the particle size of the emulsion. The titration of oleic acid/monoolein emulsion in a pH 6.5 medium with a mixed bile salt system indicated reduction in the particle size of the emulsion. Drug precipitation was observed above 30 mM bile salt concentrations. No drug crystals could be detected in the intestinal contents of the rats when emulsion formulations were ingested. These results suggest that in the intestine of the animals, the particle size of the emulsions is reduced in the presence of bile fluid while the drug resides primarily in the oil phase. The mechanism of enhanced transport of I from the emulsion formulations is discussed along with the possibility of cotransport for the drug and oil. Emulsion formulations can be a potential delivery form for low-bioavailable lipid-soluble drugs.
Assuntos
Dipeptídeos/farmacocinética , Morfolinas/farmacocinética , Renina/antagonistas & inibidores , Absorção/efeitos dos fármacos , Administração Oral , Animais , Ácidos e Sais Biliares/farmacologia , Química Farmacêutica/métodos , Dipeptídeos/administração & dosagem , Emulsões , Glicerídeos/farmacologia , Mucosa Intestinal/metabolismo , Masculino , Morfolinas/administração & dosagem , Boca/metabolismo , Ácido Oleico , Ácidos Oleicos/farmacologia , Ratos , Ratos Sprague-Dawley , SolubilidadeRESUMO
The metabolism of actisomide, a novel antiarrhythmic agent, was studied in the dog, monkey and man and was found to be more extensive in the monkey than in the dog or man. The major metabolites identified were a piperidinyl hydroxylated metabolite, the mono-N-dealkylated, cyclized and piperidine hydroxylated metabolite, and the cyclized and mono-N-dealkylated metabolite. Excretion of the parent drug was higher in urine than in feces in the dog, but in the monkey and man, urinary and fecal excretion of actisomide was similar. In all species the metabolites were primarily excreted in feces.
Assuntos
Antiarrítmicos/metabolismo , Pirimidinonas/metabolismo , Adulto , Animais , Radioisótopos de Carbono , Remoção de Radical Alquila , Cães , Fezes/química , Humanos , Macaca mulatta , Masculino , Especificidade da EspécieRESUMO
A technique is described for the collection of blood samples after dilation of rat tail veins using a controlled temperature device. Frequent blood samples of seven or eight per rat were collected during a 6-hr period. Further samples were taken from the same vein after recannulation during the next 5 days. This technique was also used to administer drugs intravenously through one vein and to collect blood samples from the contralateral vein.
Assuntos
Coleta de Amostras Sanguíneas/métodos , Cauda/irrigação sanguínea , Animais , Temperatura Alta , Masculino , Ratos , Ratos Endogâmicos , VeiasRESUMO
In enriched canine parietal cell preparations, misoprostol, an analog of prostaglandin E1 methyl ester, was rapidly deesterified to misoprostol free acid. Under this circumstance, misoprostol and misoprostol free acid exhibited equal antisecretory potency against histamine-stimulated acid secretion and bound equally well to prostaglandin E receptors. When the deesterification of misoprostol was inhibited by paraoxon, an esterase inhibitor, the antisecretory and receptor binding activity of misoprostol was markedly reduced, with potency much less than misoprostol free acid. These results indicate that misoprostol free acid is the active biological form of misoprostol that binds to prostaglandin E receptors and mediates the antisecretory action of misoprostol.